TFA
SVA

Transamerica Financial Advisors’s Sinovac Biotech, Ltd SVA Stock Holding History

Transamerica Financial Advisors’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Hold
1
– – ﹤0.01% 2305
2026
Q1 		$0 Hold
1
– – ﹤0.01% 2126
2025
Q4 		$0 Sell
1
-1
-50% – ﹤0.01% 1936
2025
Q3 		$0 Hold
2
– – ﹤0.01% 1609
2025
Q2 		$0 Buy
+2
New – ﹤0.01% 594
2024
Q4 		– Sell
-2
Closed – – 599
2024
Q3 		$0 Hold
2
– – ﹤0.01% 668
2024
Q2 		$1K Hold
2
– – ﹤0.01% 557
2024
Q1 		$1K Hold
2
– – ﹤0.01% 604
2023
Q4 		$1K Hold
2
– – ﹤0.01% 626
2023
Q3 		$0 Hold
2
– – ﹤0.01% 661
2023
Q2 		$0 Buy
+2
New – ﹤0.01% 651
2023
Q1 		– Sell
-2
Closed – – 728
2022
Q4 		$0 Hold
2
– – ﹤0.01% 720
2022
Q3 		$0 Hold
2
– – ﹤0.01% 689
2022
Q2 		$1K Buy
+2
New +$1K ﹤0.01% 668

Other funds holding SVA

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return
HI
Horizon Investments Charlotte, North Carolina $9.13B AUM 34.49% 1-Year Est. Return

Transamerica Financial Advisors's SVA Position: Q2 2026 in Review

Transamerica Financial Advisors held its Sinovac Biotech, Ltd (SVA) position steady in Q2 2026 at 1 share worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2305.

Transamerica Financial Advisors first reported a position in SVA in Q2 2022 and has held it in 14 quarters since. The position peaked at $1K in Q2 2024. 29 funds tracked by Wall St. Rank hold SVA as of Q2 2026.

  • Transamerica Financial Advisors held 1 share of Sinovac Biotech, Ltd worth $0 as of Q2 2026.
  • Transamerica Financial Advisors left its Sinovac Biotech, Ltd share count unchanged in Q2 2026.
  • Sinovac Biotech, Ltd made up ﹤0.01% of Transamerica Financial Advisors's portfolio in Q2 2026, its #2305 holding.
  • Transamerica Financial Advisors first reported a position in Sinovac Biotech, Ltd in Q2 2022 and has held it in 14 quarters since.
  • Transamerica Financial Advisors's Sinovac Biotech, Ltd position peaked at $1K in Q2 2024.
  • 29 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2026.

Based on Transamerica Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.